Anixa Biosciences, Inc.ANIXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank56
3Y CAGR-42.4%
5Y CAGR+68.8%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-42.4%/yr
vs +111.6%/yr prior
5Y CAGR
+68.8%/yr
Recent deceleration
Acceleration
-154.0pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
13.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q1 2026 | 5.56% |
| Q4 2025 | -18.06% |
| Q3 2025 | 18.88% |
| Q2 2025 | 11.31% |
| Q1 2025 | -7.05% |
| Q4 2024 | 11.94% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.47% |
| Q1 2024 | -18.29% |
| Q4 2023 | -7.28% |
| Q3 2023 | -11.09% |
| Q2 2023 | -0.16% |
| Q1 2023 | 29.18% |
| Q4 2022 | -29.03% |
| Q3 2022 | 22.07% |
| Q2 2022 | 7.50% |
| Q1 2022 | 4.83% |
| Q4 2021 | 7.09% |
| Q3 2021 | -80.05% |
| Q2 2021 | -9.14% |
| Q1 2021 | 0.41% |
| Q4 2020 | 7.95% |
| Q3 2020 | 8.77% |
| Q2 2020 | -1.53% |
| Q1 2020 | -23.55% |
| Q4 2019 | 2.55% |
| Q3 2019 | 15.76% |
| Q2 2019 | 43.19% |
| Q1 2019 | 5.38% |
| Q4 2018 | 13.93% |
| Q3 2018 | -300.14% |
| Q2 2018 | 25.27% |
| Q1 2018 | -7.88% |
| Q4 2017 | -0.39% |
| Q3 2017 | -42.81% |
| Q2 2017 | 13.11% |
| Q1 2017 | -52.74% |
| Q4 2016 | 6.32% |
| Q3 2016 | 15.11% |
| Q2 2016 | 22.01% |